News
MatrileX Highlights Preclinical Rigor Strategies in Fibrosis Research at the 9th AFDD Summit
At the 9th Antifibrotic Drug Development Summit, Dr. Yanling Zhang presented MatrileX’s research poster, “Back to the Future: Using Clinical Trial Design to Enhance the Utility of Preclinical Testing in Fibrotic Diseases.” The poster highlights strategies to...
Professor Richard E. Gilbert Co-Chairs Key Sessions at the 9th AFDD Summit
Boston, MA — November 17–19, 2025 — MatrileX Laboratories participated in the 9th Antifibrotic Drug Development Summit, a leading industry forum bringing together experts across fibrosis biology, translational research, and early clinical development. Co-Chair of...
MatrileX Laboratories Publishes New Study Defining Dose–Response Biology of Ramipril in the Alport COL4A3−/− Mouse Model
MatrileX Laboratories is pleased to announce the publication of our new peer-reviewed study, “Dose-dependent effects of the ACE inhibitor, ramipril, on kidney function and structure in the Alport COL4A3−/− mouse.” The study defines, for the first time, the functional...
MatrileX Scientists Publish New Study Establishing Novel Renal Effects of SGLT2 Inhibition
MatrileX Laboratories is pleased to highlight the publication of a new peer-reviewed study, “Induction of proximal tubular proliferation and lengthening in response to sodium–glucose cotransporter-2 inhibition in experimental rats.” This work provides mechanistic...
MatrileX demonstrates broad utility of Col4A3 KO model in CKD/DKD
MatrileX scientists establish new effects of SGLT2 inhibition on the kidney
Paddle Royale Challenge | Dr. Kim Connelly vs. Ben Stiller?!
MatrileX investigators present new findings in model of primary sclerosing cholangitis at the American Association for the Study of Liver Diseases Society’s (AASLD) 2024 annual scientific meeting.
MatrileX investigators present new findings in Alport mice at the American Society of Nephrology’s (ASN) 2024 annual scientific meeting.